Resumen
This review comprehensively summarizes the pathogenic mechanisms responsible for immune-related Adverse Events (irAEs) arising from self-tolerance loss due to Immune Checkpoint Inhibitors (ICIs) and discusses the main clinical manifestations due to irAEs categorized by organ types, their incidence, and risk factors. In addition, it focuses on the different distributions in frequencies of the diverse clinical manifestations due to irAEs between CTLA4 and PD1 pathway inhibitors and the intricate differential with primary autoimmune disorders, which share some pathophysiological and clinical aspects.